Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a phase I, clinical research study of EPI-7386, an investigational drug being studied
as a treatment for patients with prostate cancer. All patients in the study will receive
EPI-7386.
Since this is the first study of EPI-7386 in humans, there is no information about how it
affects people or what dose should be used. Therefore, the main purpose of this study is to
assess the safety (side effects) of EPI-7386 and to find a dose that can be given without
unacceptable side effects.
There are other important things that will be evaluated during the study:
- How the amount of EPI-7386 in the blood changes over time.
- The effect of EPI-7386 on prostate cancer.
- The effect of EPI-7386 on certain substances in the body.
- The possibility that EPI-7386 can interact with other drugs.